Libtayo
Libtayo® Gains FDA Approval as First Adjuvant PD-1 Therapy for High-Risk Cutaneous Squamous Cell Carcinoma
The FDA has approved cemiplimab-rwlc (Libtayo®) for adjuvant treatment of adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation. Libtayo is already approved for advanced CSCC, basal cell carcinoma, and NSCLC.